Infectious Disease Molecular Diagnostics Outlook 2015
The molecular diagnostics (MDx) market represents one of the fastest growing segments of global IVD industry. The overall market is estimated to have reached by around US$ 5.4 Billion in 2011 across the globe and is further estimated to grow at a healthy CAGR of around 10% during 2012-2015. Though a very small proportion of government expenditure is imparted for diagnostic care, it influences significant number of medical decisions. There has been a huge increase in the number of technologically advanced molecular diagnostics tests in recent times that led to create a substantial opportunity in the segment. The future landscape will also be impacted by a proliferation in tests volume and active private sector participation.
Infectious diseases account for the leading position in the global MDx market. In 2011, the market contributed around 52% to the revenue patterns attained from the sales of MDx products/technologies. Further dominated by HIV and CT/NG testing, the infectious disease market is anticipated to grow at the CAGR of around 11% during the forecast period, 2012-2015. In this context, our report “Infectious Disease Molecular Diagnostics Outlook 2015”, has effectively monitored the current and future outlook of the infectious disease MDx’s market as a whole and its segments on an individual basis. Our study has also demonstrated the leading position of key methods used in tests for infectious diseases.
There are some of the prominent players in the infectious molecular diagnostics market who are actively participating in industry development. Companies, such as Roche Molecular Diagnostics, bioMerieux, Becton and Dickinson, Abbott Molecular, and Gen-Probe are the leading market players with high-selling platforms and screening tests used for key infectious diseases. Our report provides an in-depth insight on these players in the competitive landscape section. The section covers an effective insight into the businesses of all the companies and its infectious disease-related diagnostic products.
The report, which is spread in around 90 pages, is a comprehensive analyses, covering all the key aspects of the global infectious disease market. It investigates the current market trends that impact the sector in a significant manner. Moreover, a prudent analysis on the performance of sector in key diseases have been also covered that will be a source of complete knowledge and insight for the investors/clients. Overall, the report is an optimum presentation of infectious disease diagnostics sector worldwide, which caters to all those interested in healthcare/diagnostics domain.
Infectious diseases account for the leading position in the global MDx market. In 2011, the market contributed around 52% to the revenue patterns attained from the sales of MDx products/technologies. Further dominated by HIV and CT/NG testing, the infectious disease market is anticipated to grow at the CAGR of around 11% during the forecast period, 2012-2015. In this context, our report “Infectious Disease Molecular Diagnostics Outlook 2015”, has effectively monitored the current and future outlook of the infectious disease MDx’s market as a whole and its segments on an individual basis. Our study has also demonstrated the leading position of key methods used in tests for infectious diseases.
There are some of the prominent players in the infectious molecular diagnostics market who are actively participating in industry development. Companies, such as Roche Molecular Diagnostics, bioMerieux, Becton and Dickinson, Abbott Molecular, and Gen-Probe are the leading market players with high-selling platforms and screening tests used for key infectious diseases. Our report provides an in-depth insight on these players in the competitive landscape section. The section covers an effective insight into the businesses of all the companies and its infectious disease-related diagnostic products.
The report, which is spread in around 90 pages, is a comprehensive analyses, covering all the key aspects of the global infectious disease market. It investigates the current market trends that impact the sector in a significant manner. Moreover, a prudent analysis on the performance of sector in key diseases have been also covered that will be a source of complete knowledge and insight for the investors/clients. Overall, the report is an optimum presentation of infectious disease diagnostics sector worldwide, which caters to all those interested in healthcare/diagnostics domain.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MOLECULAR DIAGNOSTICS: CURRENT AND EMERGING TECHNOLOGIES
3.1 Nucleic Acid Amplification based Technologies
3.1.1 Polymerase Chain Reaction (PCR)
3.1.2 Real Time PCR
3.1.3 Multiplex PCR
3.1.4 Transcription Mediated Amplification (TMA)
3.1.5 Nucleic Acid Sequence based Amplification (NASBA)
3.1.6 Strand Displacement Amplification (SDA)
3.2 Hybridization based Technologies
3.2.1 Microarray
3.2.2 Fluorescence in Situ Hybridization (FISH)
3.3 Sequencing based Technologies
4. INDUSTRY TRENDS AND DRIVERS
4.1 Expansions and Strategic Activity Fuelling Growth amongst Leading Players
4.2 HAI’s Diagnostics to Diversify Greatly
4.3 Next-Generation Technologies Growing in the Market
5. INDUSTRY OVERVIEW: CURRENT & FUTURE MARKET ANALYSIS TO 2015
5.1 Molecular Diagnostics Market
5.2 Infectious Disease Molecular Diagnostics Market
6. INFECTIOUS DISEASE MOLECULAR DIAGNOSTICS: MARKET SEGMENTS
6.1 HIV
6.1.1 Global Disease Burden
6.1.2 Market Size: Current and Future Analysis to 2015
6.1.3 FDA Approved Tests
6.1.4 Market Activities
6.2 Hepatitis
6.2.1 Global Disease Burden (Hepatitis B and C)
6.2.2 Market Size: Current and Future Analysis to 2015
6.2.3 FDA Approved Tests
6.2.4 Market Activities
6.3 Human Papillomavirus (HPV)
6.3.1 Global Disease Burden
6.3.2 Market Size: Current and Future Analysis to 2015
6.3.3 FDA Approved Tests
6.3.4 Market Activities
6.4 Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (GC)
6.4.1 Global Disease Burden
6.4.2 Market Size: Current and Future Analysis to 2015
6.4.3 FDA Approved Tests
6.4.4 Market Activities
7. REGULATORY FRAMEWORK
8. COMPETITIVE LANDSCAPE
8.1 Abbott Laboratories
8.2 Becton, Dickinson and Company
8.3 Siemens
8.4 bioMérieux
8.5 Gen-Probe
8.6 Cepheid
8.7 Qiagen NV
8.8 Roche
2. RESEARCH METHODOLOGY
3. MOLECULAR DIAGNOSTICS: CURRENT AND EMERGING TECHNOLOGIES
3.1 Nucleic Acid Amplification based Technologies
3.1.1 Polymerase Chain Reaction (PCR)
3.1.2 Real Time PCR
3.1.3 Multiplex PCR
3.1.4 Transcription Mediated Amplification (TMA)
3.1.5 Nucleic Acid Sequence based Amplification (NASBA)
3.1.6 Strand Displacement Amplification (SDA)
3.2 Hybridization based Technologies
3.2.1 Microarray
3.2.2 Fluorescence in Situ Hybridization (FISH)
3.3 Sequencing based Technologies
4. INDUSTRY TRENDS AND DRIVERS
4.1 Expansions and Strategic Activity Fuelling Growth amongst Leading Players
4.2 HAI’s Diagnostics to Diversify Greatly
4.3 Next-Generation Technologies Growing in the Market
5. INDUSTRY OVERVIEW: CURRENT & FUTURE MARKET ANALYSIS TO 2015
5.1 Molecular Diagnostics Market
5.2 Infectious Disease Molecular Diagnostics Market
6. INFECTIOUS DISEASE MOLECULAR DIAGNOSTICS: MARKET SEGMENTS
6.1 HIV
6.1.1 Global Disease Burden
6.1.2 Market Size: Current and Future Analysis to 2015
6.1.3 FDA Approved Tests
6.1.4 Market Activities
6.2 Hepatitis
6.2.1 Global Disease Burden (Hepatitis B and C)
6.2.2 Market Size: Current and Future Analysis to 2015
6.2.3 FDA Approved Tests
6.2.4 Market Activities
6.3 Human Papillomavirus (HPV)
6.3.1 Global Disease Burden
6.3.2 Market Size: Current and Future Analysis to 2015
6.3.3 FDA Approved Tests
6.3.4 Market Activities
6.4 Chlamydia Trachomatis (CT)/Neisseria Gonorrhoeae (GC)
6.4.1 Global Disease Burden
6.4.2 Market Size: Current and Future Analysis to 2015
6.4.3 FDA Approved Tests
6.4.4 Market Activities
7. REGULATORY FRAMEWORK
8. COMPETITIVE LANDSCAPE
8.1 Abbott Laboratories
8.2 Becton, Dickinson and Company
8.3 Siemens
8.4 bioMérieux
8.5 Gen-Probe
8.6 Cepheid
8.7 Qiagen NV
8.8 Roche
LIST OF FIGURES
Figure 5-1: Molecular Diagnostics Market (Billion US$), 2011-2015
Figure 5-2: Molecular Diagnostics Market by Segment (%), 2011
Figure 5-3: Molecular Diagnostics Market by Player (%), 2011
Figure 5-4: Share of Infectious Diseases in Molecular Diagnostics Market (2011 & 2015)
Figure 5-5: Infectious Diseases Molecular Diagnostics Market (Billion US$), 2011-2015
Figure 6-1: Infectious Diseases Molecular Diagnostics Market by Disease Segment (%), 2011 & 2015
Figure 6-2: New Cases of HIV/AIDS (Million), 2009 & 2010
Figure 6-3: Prevalence of HIV/AIDS (Million), 2011 & 2015
Figure 6-4: HIV/AIDS Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-5: Prevalence of Hepatitis B (Billion), 2011 & 2015
Figure 6-6: HBV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-7: HCV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-8: Number of New Cervical Cancer Cases (Million), 2011 & 2015
Figure 6-9: HPV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-10: CT/GC Molecular Diagnostics Market (Million US$), 2011-2015
Figure 7-1: US - Approved Molecular Diagnostic Products by Segment (%)
Figure 5-1: Molecular Diagnostics Market (Billion US$), 2011-2015
Figure 5-2: Molecular Diagnostics Market by Segment (%), 2011
Figure 5-3: Molecular Diagnostics Market by Player (%), 2011
Figure 5-4: Share of Infectious Diseases in Molecular Diagnostics Market (2011 & 2015)
Figure 5-5: Infectious Diseases Molecular Diagnostics Market (Billion US$), 2011-2015
Figure 6-1: Infectious Diseases Molecular Diagnostics Market by Disease Segment (%), 2011 & 2015
Figure 6-2: New Cases of HIV/AIDS (Million), 2009 & 2010
Figure 6-3: Prevalence of HIV/AIDS (Million), 2011 & 2015
Figure 6-4: HIV/AIDS Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-5: Prevalence of Hepatitis B (Billion), 2011 & 2015
Figure 6-6: HBV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-7: HCV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-8: Number of New Cervical Cancer Cases (Million), 2011 & 2015
Figure 6-9: HPV Molecular Diagnostics Market (Million US$), 2011-2015
Figure 6-10: CT/GC Molecular Diagnostics Market (Million US$), 2011-2015
Figure 7-1: US - Approved Molecular Diagnostic Products by Segment (%)
LIST OF TABLES
Table 3-1: Key PCR based Tests for Infectious Diseases
Table 3-2: Key Real Time PCR based Tests for Infectious Diseases
Table 3-3: Key Multiplex PCR based Tests for Infectious Diseases
Table 3-4: Key TMA based Tests for Infectious Diseases
Table 3-5: Key NASBA based Tests for Infectious Diseases
Table 3-6: Key SDA based Tests for Infectious Diseases
Table 3-7: Key Probe based Tests for Infectious Diseases
Table 3-8: Key Microarray based Tests for Infectious Diseases
Table 3-9: Key Sequencing based Tests for Infectious Diseases
Table 6-1: Prevalence of HIV/AIDS by Region (2010)
Table 6-2: FDA Approved HIV Molecular Diagnostics Tests
Table 6-3: Prevalence of Chronic Hepatitis B by Region
Table 6-4: FDA Approved Hepatitis Molecular Diagnostics Tests
Table 6-5: Contribution of HPV in Cancer by Type
Table 6-6: HPV Prevalence by Type
Table 6-7: HPV Prevalence by Region
Table 6-8: FDA Approved HPV Molecular Diagnostics Tests
Table 6-9: Estimated New Cases of Chlamydia in Adults (Million)
Table 6-10: Estimated New Cases of Gonorrhea in Adults (Million)
Table 6-11: FDA Approved CT/GC Molecular Diagnostics Tests
Table 8-1: Abbott Molecular - Infectious Disease Molecular Diagnostic Products
Table 8-2: BD Diagnostics - Infectious Disease Molecular Diagnostic Products
Table 8-3: Siemens Healthcare - Infectious Disease Diagnostic Products
Table 8-4: bioMerieux - Infectious Disease Molecular Diagnostic Products
Table 8-5: Gen-Probe - Key Infectious Disease Diagnostic Products
Table 8-6: Cepheid - Infectious Disease Diagnostic Products
Table 8-7: Qiagen N.V. - Infectious Disease Diagnostic Products
Table 8-8: Roche Molecular Diagnostics - Infectious Disease Diagnostics Products
Table 3-1: Key PCR based Tests for Infectious Diseases
Table 3-2: Key Real Time PCR based Tests for Infectious Diseases
Table 3-3: Key Multiplex PCR based Tests for Infectious Diseases
Table 3-4: Key TMA based Tests for Infectious Diseases
Table 3-5: Key NASBA based Tests for Infectious Diseases
Table 3-6: Key SDA based Tests for Infectious Diseases
Table 3-7: Key Probe based Tests for Infectious Diseases
Table 3-8: Key Microarray based Tests for Infectious Diseases
Table 3-9: Key Sequencing based Tests for Infectious Diseases
Table 6-1: Prevalence of HIV/AIDS by Region (2010)
Table 6-2: FDA Approved HIV Molecular Diagnostics Tests
Table 6-3: Prevalence of Chronic Hepatitis B by Region
Table 6-4: FDA Approved Hepatitis Molecular Diagnostics Tests
Table 6-5: Contribution of HPV in Cancer by Type
Table 6-6: HPV Prevalence by Type
Table 6-7: HPV Prevalence by Region
Table 6-8: FDA Approved HPV Molecular Diagnostics Tests
Table 6-9: Estimated New Cases of Chlamydia in Adults (Million)
Table 6-10: Estimated New Cases of Gonorrhea in Adults (Million)
Table 6-11: FDA Approved CT/GC Molecular Diagnostics Tests
Table 8-1: Abbott Molecular - Infectious Disease Molecular Diagnostic Products
Table 8-2: BD Diagnostics - Infectious Disease Molecular Diagnostic Products
Table 8-3: Siemens Healthcare - Infectious Disease Diagnostic Products
Table 8-4: bioMerieux - Infectious Disease Molecular Diagnostic Products
Table 8-5: Gen-Probe - Key Infectious Disease Diagnostic Products
Table 8-6: Cepheid - Infectious Disease Diagnostic Products
Table 8-7: Qiagen N.V. - Infectious Disease Diagnostic Products
Table 8-8: Roche Molecular Diagnostics - Infectious Disease Diagnostics Products
